COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,649 Articles (22,913 medRxiv, 8,736 bioRxiv)

Most recent first Previous |  Page 2019: Articles 20181-20190  | Next

Mathematical assessment of the roles of vaccination and non-pharmaceutical interventions on COVID-19 dynamics: a multigroup modeling approach
Gumel, A. B., Iboi, E. A., Ngonghala, C. N., Ngwa, G. A.
10.1101/2020.12.11.20247916 — Posted: 2020-12-14 Discussion: Onsite
COVID-19 in persons affected by Hansen's disease in Brazil
Deps, P., Repsold, T., Salgado, C., Bouth, R. d. C., Cerqueira, S. R. P. S., Brezinscki, M. S., Peixoto, R. R. G. B., Barreto, J. A., Fonseca, A., Peixoto, M., Mendes, S. U., Mendes, R. P. R., Oliveira, P. P. d. S., Gomes, C. M.
10.1101/2020.12.11.20247262 — Posted: 2020-12-14 Discussion: Onsite
Acceptability and feasibility of strategies to shield the vulnerable during the COVID-19 outbreak: a qualitative study in six Sudanese communities
Abdelmagid, N., Ahmed, S. A. E., Nurelhuda, N., Zainalabdeen, I., Ahmed, A., Fadlallah, M. A., Dahab, M.
10.1101/2020.12.14.20248160 — Posted: 2020-12-14
Modeling of aerosol transmission of airborne pathogens in ICU rooms of COVID-19 patients with acute respiratory failure
Crawford, C., Vanoli, E., Decorde, B., Lancelot, M., Duprat, C., Josserand, C., Jilesen, J., Bouadma, L., Timsit, J.-F.
10.1101/2020.12.11.20247551 — Posted: 2020-12-14
Maintenance therapy with infliximab or vedolizumab in inflammatory bowel disease is not associated with increased SARS-CoV-2 seroprevalence: UK experience in the 2020 pandemic
Gregor, C. G., Adams, A., Sadler, R., Arancibia-Carcamo, C. V., Palmer, R., Ambrose, T., Brain, O., Walsh, A., Klenerman, P., Travis, S., Croft, N. M., Lindsay, J. O., Satsangi, J.
10.1101/2020.12.12.20247841 — Posted: 2020-12-14
Risk-driven responses to COVID-19 eliminate the tradeoff between lives and livelihoods
Rahmandad, H., Lim, T. Y.
10.1101/2020.12.11.20247924 — Posted: 2020-12-14
Are commercial antibody assays substantially underestimating SARS-CoV-2 ever infection? An analysis on a population-based sample in a high exposure setting
Nasrallah, G. K., Dargham, S. R., Shurrab, F., Al-Sadeq, D. W., Al-Jighefee, H., Chemaitelly, H., Al Kanaani, Z., Al Khal, A., Al Kuwari, E., Coyle, P., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul Rahim, H. F., Yassine, H. M., Al Kuwari, M. G., Qotba, H., Al Romaihi, H. E., Tang, P., Bertollini, R., Al-Thani, M. H., Althani, A. A., Abu-Raddad, L. J.
10.1101/2020.12.14.20248163 — Posted: 2020-12-14
Predicting the Peak and COVID-19 trend in six high incidence countries: A study based on Modified SEIRD model
Bedi, P. P., Dhiman, M. S., Gupta, M. N., Jindal, D. V., Gole, M. P.
10.1101/2020.12.14.20248117 — Posted: 2020-12-14
How the COVID-19 pandemic has adversely affected the economics of U.S. emergency care
Pines, J. M., Zocchi, M. S., Black, B. S., Kornas, R., Celedon, P., Moghtaderi, A., Venkat, A.
10.1101/2020.12.12.20248102 — Posted: 2020-12-14
CD177, a specific marker of neutrophil activation, is a hallmark of COVID-19 severity and death
Levy, Y., Wiedemann, A., Hejblum, B. P., Durand, M., Lefebvre, C., Surenaud, M., Lacabaratz, C., Perreau, M., Foucat, E., Dechenaud, M., Tisserand, P., Blengio, F., Hivert, B., Gautier, M., Cervantes, M., Bachelet, D., Laouenan, C., Bouadma, l., Timsit, J.-F., Yazdanpanah, Y., Pantaleo, G., Hocini, H., Thiebaut, R., Study Group, F. C.
10.1101/2020.12.12.20246934 — Posted: 2020-12-14

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).